176 related articles for article (PubMed ID: 36111167)
1. ZFP36 Inhibits Tumor Progression of Human Prostate Cancer by Targeting CDK6 and Oxidative Stress.
Yuan D; Fang Y; Chen W; Jiang K; Zhu G; Wang W; Zhang W; You G; Jia Z; Zhu J
Oxid Med Cell Longev; 2022; 2022():3611540. PubMed ID: 36111167
[TBL] [Abstract][Full Text] [Related]
2. Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.
Lyu F; Li Y; Yan Z; He Q; Cheng L; Zhang P; Liu B; Liu C; Song Y; Xing Y
J Transl Med; 2022 May; 20(1):202. PubMed ID: 35538543
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer.
Zhu JG; Yuan DB; Chen WH; Han ZD; Liang YX; Chen G; Fu X; Liang YK; Chen GX; Sun ZL; Liu ZZ; Chen JH; Jiang FN; Zhong WD
Clin Transl Oncol; 2016 Aug; 18(8):782-91. PubMed ID: 26563146
[TBL] [Abstract][Full Text] [Related]
4. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
5. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
6. Circ_0058063 regulates CDK6 to promote bladder cancer progression by sponging miR-145-5p.
Sun M; Zhao W; Chen Z; Li M; Li S; Wu B; Bu R
J Cell Physiol; 2019 Apr; 234(4):4812-4824. PubMed ID: 30362519
[TBL] [Abstract][Full Text] [Related]
7. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
8. miR-105 inhibits prostate tumour growth by suppressing CDK6 levels.
Honeywell DR; Cabrita MA; Zhao H; Dimitroulakos J; Addison CL
PLoS One; 2013; 8(8):e70515. PubMed ID: 23950948
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6.
Wang X; Wu J; Lin Y; Zhu Y; Xu X; Xu X; Liang Z; Li S; Hu Z; Zheng X; Xie L
J Exp Clin Cancer Res; 2014 Sep; 33(1):69. PubMed ID: 25178497
[TBL] [Abstract][Full Text] [Related]
10.
Pan H; Hong Y; Yu B; Li L; Zhang X
Cancer Biother Radiopharm; 2019 Jun; 34(5):334-341. PubMed ID: 30844301
[No Abstract] [Full Text] [Related]
11. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
13. miR-196a-mediated downregulation of p27
Zhan B; Huang L; Chen Y; Ye W; Li J; Chen J; Yang S; Jiang W
Prostate; 2020 Sep; 80(12):1024-1037. PubMed ID: 32628792
[TBL] [Abstract][Full Text] [Related]
14. Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer.
Barquilha CN; Santos NJ; Monção CCD; Barbosa IC; Lima FO; Justulin LA; Pértega-Gomes N; Felisbino SL
Oxid Med Cell Longev; 2020; 2020():2148562. PubMed ID: 32411320
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Negative regulation of CDK6 expression by microRNA-126-5p and its influence on the proliferation and invasion of esophageal cancer cells.
Gu JF; Liu SG; Pan Q; Qin F; Li YY
Anat Rec (Hoboken); 2020 Nov; 303(11):2811-2820. PubMed ID: 31916689
[TBL] [Abstract][Full Text] [Related]
17. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.
Pan MZ; Song YL; Gao F
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-504 functions as a tumor suppressor in oral squamous cell carcinoma through inhibiting cell proliferation, migration and invasion by targeting CDK6.
Wang X; Chang K; Gao J; Wei J; Xu G; Xiao L; Song G
Int J Biochem Cell Biol; 2020 Feb; 119():105663. PubMed ID: 31812760
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-132/212 Upregulation Inhibits TGF-β-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4.
Fu W; Tao T; Qi M; Wang L; Hu J; Li X; Xing N; Du R; Han B
Prostate; 2016 Dec; 76(16):1560-1570. PubMed ID: 27527117
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1.
Chen JH; Liang YX; He HC; Chen JY; Lu JM; Chen G; Lin ZY; Fu X; Ling XH; Han ZD; Jiang FN; Zhong WD
Int J Biol Macromol; 2015 Nov; 81():615-23. PubMed ID: 26314905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]